Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: A clinical conundrum in the PSA era

Sanoj Punnen, Robert K. Nam

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The use of PSA for prostate cancer screening has led to a large increase in the number of men undergoing transrectal ultrasonography (TRUS) - guided biopsy of the prostate to determine the presence of prostate cancer. Recently, the indications for prostate biopsy based on PSA level have been questioned and new prostate cancer risk calculators that consider other factors related to prostate cancer have been proposed. Also, there have been significant changes over the years regarding the protocols used to sample the prostate. Most protocols recommend more extensive sampling of the prostate with more laterally directed biopsies of the peripheral zone for both initial and subsequent biopsies. There is still much controversy over the appropriate number and location of biopsy cores, and timing to optimize the diagnosis of prostate cancer on initial and repeat biopsy. Finally, discovery of a new molecular marker independent of the PSA level will be very important in the diagnosis and prognosis of prostate cancer.

Original languageEnglish (US)
Pages (from-to)192-199
Number of pages8
JournalSurgical Oncology
Volume18
Issue number3
DOIs
StatePublished - Sep 2009
Externally publishedYes

Fingerprint

Prostate
Prostatic Neoplasms
Biopsy
Therapeutics
Early Detection of Cancer
Ultrasonography

Keywords

  • Biopsy
  • Diagnosis
  • Gene fusion
  • Prostate cancer
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

@article{d412cf75dacd46a1b8d2b4ae0967b94a,
title = "Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: A clinical conundrum in the PSA era",
abstract = "The use of PSA for prostate cancer screening has led to a large increase in the number of men undergoing transrectal ultrasonography (TRUS) - guided biopsy of the prostate to determine the presence of prostate cancer. Recently, the indications for prostate biopsy based on PSA level have been questioned and new prostate cancer risk calculators that consider other factors related to prostate cancer have been proposed. Also, there have been significant changes over the years regarding the protocols used to sample the prostate. Most protocols recommend more extensive sampling of the prostate with more laterally directed biopsies of the peripheral zone for both initial and subsequent biopsies. There is still much controversy over the appropriate number and location of biopsy cores, and timing to optimize the diagnosis of prostate cancer on initial and repeat biopsy. Finally, discovery of a new molecular marker independent of the PSA level will be very important in the diagnosis and prognosis of prostate cancer.",
keywords = "Biopsy, Diagnosis, Gene fusion, Prostate cancer, Treatment",
author = "Sanoj Punnen and Nam, {Robert K.}",
year = "2009",
month = "9",
doi = "10.1016/j.suronc.2009.02.006",
language = "English (US)",
volume = "18",
pages = "192--199",
journal = "Surgical Oncology",
issn = "0960-7404",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment

T2 - A clinical conundrum in the PSA era

AU - Punnen, Sanoj

AU - Nam, Robert K.

PY - 2009/9

Y1 - 2009/9

N2 - The use of PSA for prostate cancer screening has led to a large increase in the number of men undergoing transrectal ultrasonography (TRUS) - guided biopsy of the prostate to determine the presence of prostate cancer. Recently, the indications for prostate biopsy based on PSA level have been questioned and new prostate cancer risk calculators that consider other factors related to prostate cancer have been proposed. Also, there have been significant changes over the years regarding the protocols used to sample the prostate. Most protocols recommend more extensive sampling of the prostate with more laterally directed biopsies of the peripheral zone for both initial and subsequent biopsies. There is still much controversy over the appropriate number and location of biopsy cores, and timing to optimize the diagnosis of prostate cancer on initial and repeat biopsy. Finally, discovery of a new molecular marker independent of the PSA level will be very important in the diagnosis and prognosis of prostate cancer.

AB - The use of PSA for prostate cancer screening has led to a large increase in the number of men undergoing transrectal ultrasonography (TRUS) - guided biopsy of the prostate to determine the presence of prostate cancer. Recently, the indications for prostate biopsy based on PSA level have been questioned and new prostate cancer risk calculators that consider other factors related to prostate cancer have been proposed. Also, there have been significant changes over the years regarding the protocols used to sample the prostate. Most protocols recommend more extensive sampling of the prostate with more laterally directed biopsies of the peripheral zone for both initial and subsequent biopsies. There is still much controversy over the appropriate number and location of biopsy cores, and timing to optimize the diagnosis of prostate cancer on initial and repeat biopsy. Finally, discovery of a new molecular marker independent of the PSA level will be very important in the diagnosis and prognosis of prostate cancer.

KW - Biopsy

KW - Diagnosis

KW - Gene fusion

KW - Prostate cancer

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=68849096732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68849096732&partnerID=8YFLogxK

U2 - 10.1016/j.suronc.2009.02.006

DO - 10.1016/j.suronc.2009.02.006

M3 - Article

C2 - 19282170

AN - SCOPUS:68849096732

VL - 18

SP - 192

EP - 199

JO - Surgical Oncology

JF - Surgical Oncology

SN - 0960-7404

IS - 3

ER -